ICYMI, this week we had stories about melanoma management with pembrolizumab, advances in rosacea therapy, new phase 2 data of VP-315 for BCC, and more.
Data from the KEYNOTE-942 trial was presented at the American Association for Cancer Research Annual Meeting 2023.
The association was significant after adjusting for sociodemographic factors, hair status, dietary intake, lifestyle, and psychological status.
This week's edition of the Mainstream Patient features stories about the risks of phenol peels, the pros and cons of skin cycling, how to prevent stretch marks during pregnancy, and more.
The combination of punica granatum, citrus sinesis, f. cistanche, and centella asiatica revealed improved skin moisturization, radiance, and elasticity in a new study.
Click here to answer this week's poll.
Researchers said occlusive materials used in gloves can lead to irritant contact dermatitis.
The findings suggest a need to conduct cancer screening by a detailed history and comprehensive clinical examination in patients with PsA.
Researchers said responses may depend on prior immunotherapy.
Brella received FDA clearance last week for improving excessive underarm sweating.
The expected PDUFA date is December 16, 2023.
Findings published in JDD suggest topical tranexamic acid can be used as first-line monotherapy.
The American Acne and Rosacea Society is spotlighting the issue as part of Rosacea Awareness Month.
In this week’s Pointers with Portela, the 208SkinDoc picks out affordable and travel-friendly skin care products at Target that everyone can benefit from.
A key factor associated with delayed diagnosis for non-White patients is the lack of awareness that their symptoms are associated with a treatable medical condition, according to Oma Agbai, MD, and Lisa Nyanda-Manalo, MD.
The task force defined screening as a visual skin exam by a primary care clinician for this recommendation.
Block spoke to the founder of the Eczema Sample Store over Instagram Live to bring more awareness to the company’s mission.
Researchers said the drug is capable of restoring a healthy skin biome.
Researchers identified several dermoscopic features associated with genes LINC00518, PRAME, and TERT.
Researchers also investigated how electric stimulation could be used to speed up wound healing in connection with diabetes, which affects wound healing due to impaired circulation and nerve damage.
Ritlecitinib was found to be effective and well-tolerated in patients aged 12 years and older.
Researchers said emollients markedly reduced lesions and other atopic dermatitis-related factors.
Researchers said using the injections and mesotherapy in patients with acne more effectively treated their acne.
Approval has been pushed back to June 28, 2023.
A new study revealed that psoriasis patient adherence is influenced by certain characteristics of topical medications.
Researchers pooled evidence supporting the way these 2 factors correlate.
Researchers said expression of the autoantigen was increased in patients.
Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.
Results of the phase 3 ECZTRA 6 trial found that the efficacy of the drug was maintained by more than 50% of patients at 52 weeks.